Nicotinamide Riboside (NR) for cognitive dysfunction

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 3 Aug 2026: Trial registered, NCT07741071

The trials

NCT07741071: N-AD: Orally Administered Nicotinamide Riboside Over Two Years as a Potential Disease Modifying Treatment for Alzheimer's Disease

State
Under way
Phase
Phase 2
People
270 planned
Started
26 Aug 2026
Primary completion
30 Apr 2030
Arms
Nicotinamide Riboside (NR)
Results
None posted
  1. 3 Aug 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

About the treatment

Kind of treatment: Diet or lifestyle.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.